Form 8-K BridgeBio Pharma, Inc. For: Aug 01
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
BridgeBio Pharma (BBIO) PT Lowered to $45 at Citi
August 2, 2024 12:19 PM EDTCiti analyst David Lebowitz lowered the price target on BridgeBio Pharma (NASDAQ: BBIO) to $45.00 (from $46.00) while maintaining a Buy rating.
The analyst comments "BridgeBio announced 2Q24 earnings, provided an update on its pipeline, and pointed toward key recent achievements. Mgt. also highlighted... More
